What Happened?

Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ: COLL) jumped 11.6% in the morning session after the company reported strong third-quarter 2025 financial results, beating analyst expectations and raising its full-year guidance. 

The pharmaceutical company announced net revenue of $209.4 million, a 31.4% jump year on year that exceeded Wall Street forecasts. The strong performance was driven by its portfolio of pain management medications. Following these results, Collegium lifted its financial outlook for the full year. The company raised its net revenue forecast to a range of $775 million to $785 million and its adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) projection to between $460 million and $470 million.

Is now the time to buy Collegium Pharmaceutical? Access our full analysis report here.

What Is The Market Telling Us

Collegium Pharmaceutical’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for Collegium Pharmaceutical and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 27 days ago when the stock dropped 3.9% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

Collegium Pharmaceutical is up 44.5% since the beginning of the year, and at $41.36 per share, has set a new 52-week high. Investors who bought $1,000 worth of Collegium Pharmaceutical’s shares 5 years ago would now be looking at an investment worth $2,105.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.